Daily Management Review

Bristol Myers to pay up to $11.1bn to BioNTech for cancer drug license


06/03/2025


US pharmaceutical firm Bristol Myers Squibb will spend as much as $11.1bn to Germany's BioNTech for a license related to the cancer treatment BNT327.



A 4 via flickr
A 4 via flickr
A joint press release from the companies indicates that BioNTech will obtain an initial payment of $1.5bn and will get yearly payments amounting to $2bn through the end of 2028. Moreover, the German firm can qualify for milestone payments totaling as much as $7.6bn once specific milestones are achieved. 

The collaborators will equally divide the costs of development and production along with any profits (or losses). 

Bristol Myers' stock price has increased by 1 percent in Monday's pre-market. The price of BioNTech's ADR on the Nasdaq market surged almost 12%. 

Since the start of 2025, Bristol Myers' capitalization decreased by nearly 15% (to $95.3 billion), whereas the S&P 500 stock index increased by 0.5%.

source: bloomberg.com